Abstract:2030 Background: Approximately 5% of advanced stage breast cancer (BC) will develop leptomeningeal disease, a rare form of metastasis in the meninges, a membrane surrounding the brain and spinal cord. The prognosis for BC-LMD is dismal and currently available treatments are ineffective. For example, intrathecal (IT) therapy such as trastuzumab, and proton cranial spinal radiotherapy have only showed modest success. Dendritic cells are a master regulator of the immune system and play a critical role in bridging the innate and adaptive immune response. Here, we used a novel preclinical model to administer MHC class II peptide-pulsed conventional Type 1 dendritic cells (cDC1s) intrathecally in mice that harbor either HER2+ or triple negative breast cancer (TBNC) LMD. Our murine BC-LMD murine data lead us to open a Phase 1 clinical trial of cDC1s in HER2+ and TNBC LMD (NCT05809752; in progress). Methods: Our lab developed a “murine Ommaya” which mimics the clinically used Ommaya reservoir and allows for repeated intrathecal (IT) injections of novel drugs at 3 – 7µl volume directly into the CSF. We next developed a pipeline for screening immunogenic MHC class II peptides from tumor-associated oncodrivers and using these targets to generate tumor-targeting cDC1s. We tested the resulting vaccines in a preclinical model that IT delivers peptide-pulsed cDC1 cell therapy directly into the BC-LMD microenvironment. Results: We tested the efficacy of treatment in HER2+ LMD and TNBC-LMD models and found effective responses; LMD mice that received IT cDC1 therapy exhibited reduced tumor burden and prolonged survival that was significantly better than systemic therapy. Approximately 70% of mice from HER2+ LMD and 30% from TNBC LMD demonstrated complete responses. This was CD4+ T cell dependent. Notably, cured mice also showed signs of resistance against LMD recurrence upon rechallenge. Subsequent single cell RNA-seq (scRNA-seq) analyses of the CSF showed a shift in the innate immune landscape found in untreated LMD to an adaptive immune landscape. In addition, we noted the elevated secretion of Th1 proinflammatory cytokines such as IFN-γ in the CSF. This was recapitulated in the CSF samples of patients enrolled in an on-going phase 1 trial, where early data showed IT cDC1 triggered a high concentration of several proinflammatory cytokines. Conclusions: Our preclinical data suggest IT cDC1 vaccine is effective against BC-LMD and prevents LMD recurrence. We are currently investigating the mechanism(s) by which IT cDC1-initiates the CD4 Th1 adaptive immune response against LMD. By employing an scRNA-seq approach, we hope to further determine the roles of different immune cells and their subtypes in the CSF to IT cDC1s in mice and in patients. A future approach includes testing IT cDC1 platform in LMD from other cancers (e.g. melanoma etc.).

Lectin-targeted dendritic cell immunotherapies against experimental autoimmune encephalitis/multiple sclerosis (CAM5P.242)

Efficacy of Intrathecal Delivery of Peptide-Pulsed Type 1 Conventional Dendritic Cell Vaccine for the Treatment of Breast Cancer-Associated Leptomeningeal Disease in Preclinical Models.

C16 Peptide Shown to Prevent Leukocyte Infiltration and Alleviate Detrimental Inflammation in Acute Allergic Encephalomyelitis Model

Transmigration across a Steady-State Blood-Brain Barrie Induces Activation of Circulating Dendritic Cells Partly Mediated by Actin Cytoskeletal Reorganization

Targeting CB(2) Receptor As a Neuroinflammatory Modulator in Experimental Autoimmune Encephalomyelitis.

Antineuroinflammatory and neurotrophic effects of CNTF and C16 peptide in an acute experimental autoimmune encephalomyelitis rat model.

Amelioration of experimental autoimmune encephalomyelitis by exogenous soluble PD-L1 is associated with restraining dendritic cell maturation and CCR7-mediated migration

Cd8 Alpha+ Dendritic Cells And Immune Protection From Experimental Allergic Encephalomyelitis

Dose-dependent anti-inflammatory and neuroprotective effects of an α β 3 integrin-binding peptide

Small molecule-mediated upregulation of CCR7 ameliorates murine experimental autoimmune encephalomyelitis by accelerating T-cell homing

Analysis of the Cellular Mechanism Underlying Inhibition of EAE after Treatment with Anti-Nkg2a F(ab′)2

Therapeutic Potential Of Ifn-Gamma-Modified Dendritic Cells In Acute And Chronic Experimental Allergic Encephalomyelitis

Brain innate immunity in the regulation of neuroinflammation: therapeutic strategies by modulating CD200-CD200R interaction involve the cannabinoid system

Immunoregulation of Experimental Autoimmune Encephalomyelitis by the Selective CB1 Receptor Antagonist.

Identification of essential modules regulating T cell migration to the central nervous system in multiple sclerosis

Therapeutic potential of IFN- -modified dendritic cells in acute and chronic experimental allergic encephalomyelitis

CD24 and Myosin Light Polypeptide 2 Are Involved in Prevention of Experimental Autoimmune Encephalomyelitis by Myelin Basic Protein-Pulsed Dendritic Cells.

Dectin-1 limits CNS autoimmunity through a non-canonical pathway

Using EAE to better understand principles of immune function and autoimmune pathology

Dectin-1 limits central nervous system autoimmunity through a non-canonical pathway

Targeted-Neuroinflammation Mitigation Using Inflammasome-Inhibiting Nanoligomers is Therapeutic in Experimental Autoimmune Encephalomyelitis (EAE) Mouse Model